| Entry |
|
|---|
| Name |
Oxaliplatin (JAN/USP/INN);
Eloxatin (TN) |
|---|
| Product |
|
|---|
| Generic |
OXALIPLATIN (Accord Healthcare), OXALIPLATIN (Actavis Pharma), OXALIPLATIN (Apotex Corp.), OXALIPLATIN (Athenex Pharmaceutical Division), OXALIPLATIN (AuroMedics Pharma LLC), OXALIPLATIN (Baxter Healthcare Corporation), OXALIPLATIN (BluePoint Laboratories), OXALIPLATIN (BluePoint Laboratories), OXALIPLATIN (Cipla USA), OXALIPLATIN (Fosun Pharma USA), OXALIPLATIN (Fosun Pharma USA), OXALIPLATIN (Fresenius Kabi USA), OXALIPLATIN (Gland Pharma Limited), OXALIPLATIN (Gland Pharma Limited), OXALIPLATIN (Hospira), OXALIPLATIN (Ingenus Pharmaceuticals), OXALIPLATIN (Meitheal Pharmaceuticals), OXALIPLATIN (Mylan Institutional LLC), OXALIPLATIN (Nextgen Pharmaceuticals LLC), OXALIPLATIN (NorthStar Rx LLC), OXALIPLATIN (NorthStar RxLLC), OXALIPLATIN (Qilu Pharmaceutical), OXALIPLATIN (Qilu Pharmaceutical), OXALIPLATIN (Sagent Pharmaceuticals), OXALIPLATIN (Sandoz), OXALIPLATIN (Sandoz), OXALIPLATIN (Winthrop U.S.), OXALIPLATIN (Winthrop U.S.) |
|---|
| Formula |
Pt. C6H14N2. C2O4
|
|---|
| Exact mass |
397.0601
|
|---|
| Mol weight |
397.2918
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01679 Platinum compound
Transporter substrate
DG02858 SLC22A1 (OCT1) substrate
DG02854 SLC22A2 (OCT2) substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Cell growth inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Platinum compound
DNA alkylator
|
|---|
| Target |
DNA |
|---|
| Metabolism |
Transporter: SLC22A2 [HSA: 6582], SLC22A1 [HSA: 6580]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07040 | Antineoplastics - alkylating agents |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XA Platinum compounds
L01XA03 Oxaliplatin
D01790 Oxaliplatin (JAN/USP/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01790 Oxaliplatin (JAN/USP/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01790
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01790
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01790
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D01790
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 15
1 O6a O 27.6304 -16.6769 #-
2 C6a C 28.8402 -17.3773
3 C6a C 30.0500 -16.6769
4 O6a O 31.2599 -17.3773 #-
5 O6a O 28.8402 -18.7782
6 O6a O 30.0500 -15.2761
7 C1x C 18.8079 -16.6698
8 C1x C 18.8079 -18.0706
9 C1x C 20.0240 -18.7710
10 C1y C 21.2329 -18.0706
11 C1y C 21.2329 -16.6698
12 C1x C 20.0240 -15.9694
13 N1a N 22.4327 -15.9781
14 N1a N 22.4241 -18.7572
15 Z Pt 24.9608 -17.2359 #2+
BOND 13
1 2 3 1
2 3 4 1
3 2 5 2
4 1 2 1
5 3 6 2
6 7 8 1
7 8 9 1
8 9 10 1
9 10 11 1
10 11 12 1
11 12 7 1
12 11 13 1 #Up
13 10 14 1 #Down
|
|---|
